Opus Genetics Unveils Fully Funded Plan for Five Gene Therapy Programs, Clinical Starts Through 2027
IRD has more than doubled off its 52-week low of $0.901 on light trading volume (0.3× avg).
Summary
Opus Genetics announced a fully funded plan to advance five inherited retinal disease (IRD) gene therapy programs, with clinical starts scheduled through 2027. This includes Phase 3 dosing for LCA5 in October 2026, and initiations for RDH12, MERTK, and RHO programs from Q4 2026 to 2H 2027. The company states its current cash runway extends into 2029, funding these programs to potential approvals. This news follows the previously announced strategic financing of up to $155 million and Q1 results that extended the cash runway. This detailed pipeline roadmap and confirmed funding are significant for a clinical-stage biotech, providing clarity on future milestones and financial stability.
At the time of this announcement, IRD was trading at $3.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $313.4M. The 52-week trading range was $0.90 to $5.81. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.